ImmunoGen Balance Sheet Health
Financial Health criteria checks 6/6
ImmunoGen has a total shareholder equity of $178.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $358.8M and $180.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$309.51m |
| Equity | US$178.01m |
| Total liabilities | US$180.79m |
| Total assets | US$358.80m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IMU's short term assets ($330.4M) exceed its short term liabilities ($103.6M).
Long Term Liabilities: IMU's short term assets ($330.4M) exceed its long term liabilities ($77.2M).
Debt to Equity History and Analysis
Debt Level: IMU is debt free.
Reducing Debt: IMU currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMU has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 10.9% each year.